IRVINE, Calif.--(BUSINESS WIRE)--Pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC (www.hairdx.com) today unveiled the next generation of its HairDX (RxR) Genetic Test for Finasteride response. In addition to predicting Finasteride response for the treatment of common hair loss (Androgenetic Alopecia), the test helps doctors assess if a patient has an increased risk of developing Benign Prostatic Hyperplasia (Enlarged Prostate).
